Since 2014, six different inhibitors of PD-1 and PD-L1 were approved for cancer immunotherapy by the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) (1), revolutionizing the treatment of certain cancers. Here, PDCD1 is linked to cancer.